<DOC>
	<DOCNO>NCT00392093</DOCNO>
	<brief_summary>Hypothesis , HRT increase risk lupus activity exacerbation , effective relief menopausal symptoms improve bone mineral density . Double-blind , randomize , placebo control clinical trial . Objectives 1 . Determine effect HRT disease activity , menopausal symptom , bone mineral density , lipid profile , mammographic parenchymal density menopausal woman SLE . 2 . Determine incidence rate major side effect HRT menopausal woman SLE . Outcome Measures 1 . Primary outcome global disease activity throughout follow-up period . 2 . Incidence lupus flare , time first flare , change SLEDAI value baseline follow-up visit , maximum disease activity , lupus treatment , hospitalization , thromboses , death . Menopausal symptoms depression assess utilizing Greene Climacteric Scale questionnaire Beck Depression Inventory . Bone mineral density lumbar spine hip perform dual energy x-ray absorptiometry . In addition , blood urine sample measure biochemical marker bone turnover . Estradiol level , lipid profile , coagulation test , cervical cytology examination , mammography . Inclusion Criteria : ( Any two follow criterion ) 1 . Amenorrhea 6 month 2 . Serum FSH level 30 IU/L 3 . Menopausal symptoms 4 . Age 48 year old . Exclusion Criteria : 1 . Women old 65 year 2 . Severe lupus activity baseline 3 . Use estrogens within 3 month screen visit 4 . Serum creatinine 2.0 mg/dL 5 . Hypertriglyceridemia 500 mg/dL 6 . Metabolic bone diseases 7 . Liver disease 8 . Untreated hyperthyroidism 9 . Recent thrombosis 10 . Malignancy 11 . Endometrial hyperplasia 12 . Undiagnosed uterine bleed 13 . Cervical dysplasia . Subject allocation Random assign , use computer-generated randomization list : Conjugated equine estrogens 0.625 mg/day plus 5 mg/day medroxyprogesterone acetate p.o . first 10 day per-month , biologically inert placebo.All woman receive 1200 mg calcium carbonate 800 IU vitamin D , daily . Follow-up procedure All patient evaluate rheumatologist reproductive health specialist baseline,1,2,3,6,9,12,15,18,21 , 24 month . Rheumatic evaluation : 1 . General information ( baseline ) . 2 . Lupus activity ( every visit ) . 3 . Medications : ( every visit ) Gynecological evaluation : Onset symptom since previous visit use standardized questionnaire . In addition , gynecological examination perform . Criteria early termination study : A patient discontinue study whenever follow criterion would present : 1 . Development severe lupus activity ( SLEDAI &gt; 30 ) . 2 . Development putative complication hormone therapy . 3 . Development severe complication due neither SLE hormone therapy . 4 . Need prolonged immobilization . Statistical analysis : Between-group comparison lupus activity , maximum SLEDAI , change SLEDAI score baseline follow-up visit . Incidence-density rate flare relative risk 95 percent confidence intervals.Probability flare throughout study use life-table analysis log-rank test . Climacteric symptom mean value Green ’ scale score baseline follow-up visit , between-group intra-group . Bone mineral density mean value baseline , 12 24 month , intra-group . The proportion patient group develop secondary effect , well number quit study follow-up period . Continuous variable compare use Student 's t-test , categorical variable use chi-square Fisher ’ exact test . Within-group comparison do use Wilcoxon signed-rank test . P value two-sided . Analyses conduct intention-to-treat method .</brief_summary>
	<brief_title>Effect Hormone Replacement Therapy Lupus Activity</brief_title>
	<detailed_description>Background Systemic Lupus Erythematosus ( SLE ) autoimmune disease unknown cause . Risk factor propose important pathogenesis SLE include genetic , environmental , hormonal factor ( 1 ) . Strong evidence implicates sex steroid hormone pathogenesis SLE autoimmune disease human being . Female gender consider strong risk factor development SLE ( 2 ) , incidence 8 time higher female male reproductive year . This difference susceptibility develop SLE strongly suggest influence sex hormone . We show significantly increase risk develop SLE among postmenopausal woman estrogen replacement therapy compare postmenopausal woman take hormone ; increase risk directly related length use therapy ( 3 ) . Lupus flare report period major sex hormone change puberty , menses , pregnancy postpartum ( 4-7 ) . Abnormal metabolism estrogens yield excess production 16-alpha-hydroxyestrone patient SLE sex ( 8 ) , low plasma androgen level report woman active quiescent disease ( 9,10 ) . An association SLE Klinefelter 's syndrome propose ( 11 ) . Estrogen receptor find OKT8-positive lymphocyte ( 12 ) . Studies animal model SLE also show relevance sex hormone development course SLE . Studies NZB/W F1 hybrid mouse support role female hormone modulation autoantibody production , development renal disease , death ( 13 ) . Female NZB/W F1 mouse high autoantibody titer die several month earlier male . Treatment androgens improve survival reduces immune-complex deposit development renal disease NZB/W F1 female ( 14 ) . Prepubertal castration NZB/W F1 male plus administration exogenous estrogen cause female pattern lupus ( 15 ) . In general , study consistently suggest interaction sex hormone immune system . In Institute 1900 SLE patient followed-up regularly ; 95 percent female , around 20 percent postmenopausal . These figure reflect increase number woman lupus reach postmenopausal stage due susceptibility develop either early premature menopause , along extraordinary improvement prognosis survival rate . ( 16,2 ) . Menopause entail risk develop vasomotor symptom , well chronic condition , e.g . osteoporosis . Hormone therapy , estrogens alone combination progestin , constitutes effective treatment vasomotor urogenital symptom . Current guideline recommend hormone therapy , lowest effective dose short time necessary ( 17 ) . The risk exogenous estrogen develop systemic lupus erythematosus disease activity controversial . Women user oral contraceptive ( 18 ) menopause hormonal therapy increase risk develop systemic lupus erythematosus non-users ( 3,19 ) . While high rate flare woman take combined oral contraceptive report ( 6 ) , recently , investigator Safety Estrogens Lupus Erythematosus National Assessment ( SELENA ) group demonstrate estrogen contain oral contraceptive increase risk activity exacerbation ( 20,21 ) . Hormone therapy safe , well tolerate , increase risk lupus flare observational study ( 22-24 ) ; however , SELENA group detect slight increase risk develop mild/moderate , severe flare ( 25 ) . Considering increase number woman systemic lupus erythematosus become postmenopausal , early age menopause onset , co-morbidity append ; aim evaluate effect hormone therapy disease activity , menopausal symptom , bone mineral density , lipid profile , mammographic breast density peri/postmenopausal woman systemic lupus erythematosus . We consider study help identify benefit major adverse effect , associate hormone replacement therapy peri/postmenopausal woman SLE , determine efficacy unknown field . Previous similar study Few study explore influence hormone replacement therapy activity SLE . Arden et al . ( 22 ) , conduct retrospective study among 60 postmenopausal woman SLE include 30 woman user 30 woman non-users HRT . The mean follow-up 12 month . There significant difference parameter measure include lupus activity . They conclude HRT appear well tolerate safe . Kreidstein et al. , case-control study ( 23 ) , compare incidence lupus flare 16 lupus patient receive HRT 32 control . After 12 month follow-up , author conclude use HRT postmenopausal female SLE appear increase rate lupus flare . Mok et al compare frequency severity flare 11 patient receive HRT 23 patient . No significant increase rate magnitude flare couldbe demonstrate patient receive HRT median follow-up period 35 month ( 24 ) . Although estrogen avoid SLE patient , recently consider safety estrogens lupus unsolved . The U.S. National Institutes Health fund consider first clinical trial safety estrogens woman SLE -SELENA ( Safety Estrogen Lupus Erythematosus National Assessment ) . This clinical trial conduct 5 U.S. rheumatology center . It consider `` result trial provide scientific evidence support physician ' decision safety provide oral contraceptive hormone replacement therapy ( HRT ) woman SLE '' ( 21,25 ) . Hypothesis Hormone therapy increase risk lupus activity exacerbation , effective relief menopausal symptoms improve bone mineral density . Design methodology Design : Double-blind , randomize , placebo control clinical trial . Patients : One hundred six peri/postmenopausal woman diagnosis SLE accord American College Rheumatology classification criterion ( 31 ) , follow regularly , baseline,1,2,3,6,9,12,15,18,21 24 month , assess SLE activity well efficacy , safety acceptability hormone replacement therapy . Objectives 1 . Determine effect hormone replacement therapy disease activity peri/postmenopausal woman Systemic Lupus Erythematosus . 2 . Determine effect hormone replacement therapy relief menopausal symptom , bone mineral density peri/postmenopausal woman systemic lupus erythematosus . 3 . Determine effect hormone replacement therapy lipid profile , mammographic parenchymal density peri/postmenopausal woman Systemic Lupus Erythematosus . 4 . Determine incidence rate major side effect hormone replacement therapy peri/postmenopausal woman systemic lupus erythematosus . Outcome Measures . Lupus activity : In order measure lupus activity , use validate disease activity index , Systemic Lupus Erythematosus disease activity index ( SLEDAI ) ( 26 ) . The primary outcome global disease activity throughout follow-up period , estimate area SLEDAI-curve ( SLEDAI-AUC ) . Secondary outcome incidence lupus flare , time first flare , change SLEDAI value baseline follow-up visit , maximum disease activity . Lupus flare severe flare define increase SLEDAI 3 12 point , respectively , previous visit ( 27 ) . The data also analyze use new version SLEDAI ( SLEDAI-2K ) ( 28 ) , modify SLEDAI ( SLEDAIm ) exclude microhematuria pyuria may associate treatment . We also record lupus treatment , hospitalization , thromboses , death . Menopausal symptom : Menopausal symptoms depression assess face-to face interview , utilize Greene Climacteric Scale questionnaire ( 29 ) Beck ’ Depression Inventory ( 30 ) . The Greene Climacteric Scale administer baseline , Beck ’ Depression Inventory baseline , 6 , 12 24 month treatment . Bone mineral density : Densitometry lumbar spine hip perform baseline , 12 24 month dual energy x-ray absorptiometry . In addition , blood urine sample measure biochemical marker bone turnover take baseline , 6 , 12 24 month . Other measurement : Blood sample collect estradiol baseline,1,2,3,6 15 month ; lipid profile baseline , 9 21 month ; coagulation test baseline,1 3 month ; cervical cytology examination baseline , 12 24 month ; mammography baseline last study visit patient would complete &gt; 12 month follow-up . Criteria selection subject Patients select lupus clinic Instituto Nacional de Ciencias Medicas Nutricion Salvador Zubiran . Eligible patient identify research assistant attend clinical appointment outpatient , invite participate study . Inclusion Criteria : ( Eligible woman two follow criterion ) 1 . Amenorrhea 6 month . 2 . Serum follicle-stimulating hormone level 30 IU/L . 3 . Menopausal symptom . 4 . Age 48 year old . Exclusion Criteria : 1 . Women old 65 year . 2 . Severe lupus activity baseline ( SLEDAI score , 30 ) . 3 . Use estrogens within 3 month screen visit . 4 . Serum creatinine 2.0 mg/dL . 5 . Hypertriglyceridemia 500 mg/dL . 6 . Metabolic bone disease . 7 . Liver disease . 8 . Untreated hyperthyroidism . 9 . Recent thrombosis . 10 . Malignancy . 11 . Endometrial hyperplasia . 12 . Undiagnosed uterine bleed cervical dysplasia Use hospital record : Hospital record need order complete patient ' information relate date entry hospital , first criterion , 4 criterion , chronic damage , sociodemographic information , etc. , lupus activity secondary effect hormone therapy , collect prospectively . Medical record use authorized appropriate hospital authority . This authorization implicit approval form ethic committee . Subject allocation Patients fulfill selection criterion randomly assign hormone therapy placebo , use computer-generated randomization list . Patients allocate random number accord entrance study , inform study sign acceptance form . The allocation do research assistant . Description medication study 1 . Conjugated equine estrogens 0.625 mg/day plus 5 mg/day medroxyprogesterone acetate p.o . first 10 day per-month ( Premarin Cycrin , respectively , Laboratorios Wyeth ) . 2 . Biologically inert placebo identical appearance packaging size active regimen . 3 . All woman receive daily supplement 1200 mg calcium carbonate 800 IU vitamin D ( Caltratate D , Laboratorios Whitehall-Robbins ) . Admission procedure Procedure patient recruitment : All SLE patient identify lupus clinic . If patient would accept participate , ask sign consent form study number assign research assistant . Follow-up procedure All patient evaluate standardized way date ( ± 7 day ) two independent specialist : rheumatologist reproductive health specialist . Both evaluation do baseline,1,2,3,6,9,12,15,18,21 , 24 month . Rheumatic evaluation : Each patient evaluate rheumatologist entry every follow-up visit . The following variable evaluate . 1 . - General information : ( basal evaluation ) . A standardized entry form filled-out every patient enter study . 2 . - Lupus activity : ( every visit ) This evaluate use SLEDAI ( 26 ) , widely use validated lupus activity index . A training session use index conduct participate rheumatologist order reach agreement use diminish inter-observer variability . 3 . - Medications : ( every visit ) Use medication record , continuous ( dose ) binary ( yes/no ) scale . The following medication record : steroid , azathioprine , 6-mercaptopurine , cyclophosphamide , chloroquine . Non-steroidal antiinflamatory drug record binary scale . Study treatment evaluation : After complete rheumatic evaluation , patient interview onset symptom since previous visit specialist Biology Reproduction , unblinded treatment assign . A standardized questionnaire purpose use . In addition , investigator perform gynecological physical examination , evaluate compliance treatment . The pharmacy personnel dispense study medication accord randomization list . Women attend schedule visit contact social worker , visit home require . Criteria early termination study : A patient discontinue study whenever follow criterion would present : 1 . Development severe lupus activity ( SLEDAI &gt; 30 ) . 2 . Development putative complication hormone therapy ( thrombosis , cholestasis , etc. ) . 3 . Development severe complication due neither SLE hormone therapy . 4 . Need prolonged immobilization . The decision take special meeting hold study 's physician . It require agreement least one physician participate department ( Rheumatology Reproduction Biology ) . Data management An entry form patient ( original copy ) filled-out reproductive health clinic lupus clinic . On follow-up visit , standardize form ( original copy ) fill patient clinic . The information form enter ( double entry ) master process file update week . All paper form keep special locked cabinet . Study investigator person access information order maintain absolute confidentiality . Data analysis Final analysis undertaken 24 month follow-up complete subject . Population analysis : All patient enter study include analysis . The analysis period basal evaluation last patient ’ visit study end . Statistical analysis : Lupus disease activity analyze between-group comparison lupus activity measure SLEDAI-AUC , maximum SLEDAI , change SLEDAI score baseline follow-up visit . nalysis incidence flare base incidence-density rate , patient-years follow-up denominator relative risk 95 percent confidence interval measure association . For patient , time calculate baseline first flare , withdrawal study , end follow-up , death , whichever first . The probability flare throughout study calculate use life-table analysis log-rank test . Climacteric symptom analyze mean value Green ’ scale score baseline follow-up visit , between-group intra-group . Bone mineral density analyze mean value baseline , 12 24 month , between-group intra-group . The safety acceptability hormone therapy analyze proportion patient group develop secondary effect , well number quit study follow-up period . Continuous variable compare use Student 's t-test , categorical variable use chi-square Fisher ’ exact test . Within-group comparison make use Wilcoxon signed-rank test . P value two-sided . All analysis conduct intention-to-treat method . Safety Monitoring Committee : An independent Safety Monitoring Committee consist 2 rheumatologist , 1 epidemiologist/ biostatistician , 2 endocrinologist , participate investigator establish . The committee meet every 12 month , time unusual problem occur , review unacceptable event define investigator plan phase , determine whether may attributable treatment study . The study stop Safety Monitoring Committee number unacceptable event reach stop criterion . The committee also review interim analysis , authority stop study significant difference ( P &lt; 0.01 ) detect . Missing observation : We try miss data , however , study involve several variable expect miss . We consider percentage miss observation small random , due prospective nature study . Anyway , seek advice statistician best way handle problem Preliminary ( Interim ) analysis : Since consider enough patient detect significant treatment difference earlier , mid-term preliminary analysis do 18 month . The objective analysis evaluate important difference two group related disease activity adverse effect . If satisfactory answer main study hypothesis unexpectedly high number thrombotic event would present hormone therapy group , study finish . As stopping rule , two-tailed significance level SLE activity P &lt; 0.01 establish , presence &gt; 3 thrombotic event hormone therapy group . If P value 0.01 - 0.05 detected interim analysis , second analysis undertaken 9 month later identical stopping rule SLE activity thrombosis . Preliminary analysis do personnel Clinic Epidemiology Unit Institute , blind group ' coding . Results review member Safety Monitoring Committee . The result inform research group , unless indication termination study would present . Final analysis undertaken 12 month follow-up complete subject . Number subject statistical power Sample Size : On assumption mean ( +SD ) baseline SLEDAI value 5.43±5.04 ( 27 ) , estimate plan sample size would provide 80 percent chance detect difference SLEDAI 3 point ( scale 0 105 , high score indicate great severity ) , significance level 0.05 . With allowance 20 percent loss follow-up , plan sample size 54 patient per group . Monitoring study progress : A monthly meeting hold among study participant order evaluate study 's flow , solve problem , evaluate intermediate outcome , reach agreement . Decisions foreseen begin study take meeting . Minutes write meeting file research book . Duration project ( table 1 ) Table 1.- Study 's timetable Activities Months 1-4 5-8 9-12 13-16 17-18 19-22 23-26 27-30 31- 36 Study form ** Training phase ** Lab Organization ** Monthly meeting **** **** **** **** **** **** **** **** *** Patient enrollment 1-14 15-42 43-70 71-98 99-106 Patient follow-up 1-14 1-42 15-70 43-98 71-106 99-106 Patient study end 1-14 15-42 43-70 71-98 99-106 Study 's analysis *** Manuscript 's preparation *** End study *** 3.4 Project management General coordination , supervision analysis study principal investigator responsibility . Funds administration Institute administrative office research project . All publication derive present investigation do accord establish regulation , give recognition support receive . Links project N.A . Main problem anticipate 1 . Meet study 's subject number . This main problem face . Although follow regularly around 1900 SLE patient , find 106 peri/postmenopausal woman would accept participate study review inclusion/exclusion criterion remain hard number reach . However , every year 200 new SLE patient come Institute . We expect meet necessary number conduct study . If notice low number , invite lupus patient institution participate . 2 . We consider may problem neither evaluation rheumatology reproductive health clinic . Expected outcomes study The result expect study provide light several unanswered question : 1 . - We able determine whether postmenopausal hormone therapy affect SLE activity . 2 . - We able determine effect hormone replacement therapy climacteric symptom bone mineral density peri/postmenopausal woman SLE . 3 . - We able determine incidence rate secondary effect risk/benefit profile hormone replacement therapy peri/postmenopausal woman SLE . 4 . We expect publish result first line journal . 3.8 References . 1 . - Alarcon-Segovia D. The Pathogenesis Immune Dysregulation Systemic Lupus Erythematosus . A Troika . J Rheumatol 1984 ; 11:588-90 . 2 . - Systemic Lupus Erythematosus . In : Silman AJ Hochberg MC , eds . Epidemiology Rheumatic Diseases . New York : Oxford University Press Inc. ; 1993:163-91 . 3 . - Sanchez-Guerrero J , Liang MH , Karlson EW , Hunter DJ , Colditz GA. Postmenopausal Estrogen Therapy The Risk Developing Systemic Lupus Erythematosus . Ann Intern Med 1995 ; 122:430-3 . 4 . - Rose E , Pillsbury DM . Lupus Erythematosus Ovarian Function : Observations possible relationship report 6 case . Ann Intern Med 1944 ; 21:1022-34 . 5 . - Mund A , Swison J , Rothfield N. Effect pregnancy course SLE . JAMA 1963 ; 183:917-20 . 6 . - Jungers P , Dougados M , Pelissier C , Kuttenn F , Tron F , Lesavre P , col . Influence oral contraceptive therapy activity Systemic Lupus Erythematosus . Arthritis Rheum 1982 ; 25:618-23 . 7 . - Barret C , Neylon N , Snaith ML . Oestrogen-Induced Systemic Lupus Erythematosus . Br J Rheumatol 1986 ; 25:300-1 . 8 . - Lahita RG , Bradlow HL , Kunkel HG , Fishman J . Increased 16-alpha Hydroxylation Estradiol Systemic Lupus Erythematosus . J Clin Endocrinol Metab 1981 ; 53:174-8 . 9 . - Jungers P , Nahoul K , Pelissier C , Dougados M , Tron F , Bach JF . Low Plasma Androgens Women Active Quiescent Systemic Lupus Erythematosus . Arthritis Rheum 1982 ; 25:454-7 . 10 . - Lahita RG , Bradlow HL , Ginzler E , Pang S , New M. Low Plasma Androgens Women Systemic Lupus Erythematosus . Arthritis Rheum 1987 ; 30:241-8 . 11 . - Stern R , Fishman J , Brusman H , Kunkel HG . Systemic Lupus Erythematosus associate Klinefelter 's syndrome . Arthritis Rheum 1977 ; 20:18-22 . 12 . - Cohen JHM , Danel L , Cordier G , Saez S , Revillard JP . Sex Steroid Recptors Peripheral T Cells : Absence Androgen Receptors Restriction Estrogen Receptors OKT8-Positive Cells . J Immunol 1983 ; 131:2767-71 . 13 . - Kelley VE , Winkelstein A. Age- Sex-related Glomerulonephritis New Zealand White Mice . Clin Immunol Immunopathol 1980 ; 16:142-50 . 14 . - Roubinian JR , Talal N , Greenspan JS , Goodman JR , Siiteri PK . Delayed Androgen Treatment Prolongs Survival Murine Lupus . J Clin Invest 1979 ; 63:902-11 . 15 . - Roubinian JR , Talal N , Greenspan JS , Goodman JR , Siiteri PK . Effect castration sex hormone treatment survival , anti-nucleic acid antibody , glomerulonephritis NZB/NZW F1 mouse . J Exp Med 1978 ; 147:1568-83 . 16 . Sánchez-Guerrero J , Romero-Díaz J , Mendoza-Fuentes A , Mestanza-Peralta M , Cravioto MC . Menopause Systemic Lupus Erythematosus . Age Presentation Clinical Characteristics . Arthritis Rheum 1998 ; 41 : S67 17 . The North American Menopause Society . Recommendations estrogens progestogen use peri- postmenopausal woman : October 2004 Position Statement North American Menopause Society . Menopause 2004 ; 11:589-600 . 18 . Sánchez-Guerrero J , Karlson EW , Liang MH , Hunter DJ , Speizer FE , Colditz GA. Past use oral contraceptive risk develop systemic lupus erythematosus . Arthritis Rheum 1997 ; 40:804-8 . 19 . Meier CR , Sturkenboom MC , Cohen AS , Jick H. Postmenopausal estrogen replacement therapy risk develop systemic lupus erythematosus discoid lupus . J Rheumatol 1998 ; 25:1515-9 . 20 . Sánchez-Guerrero J , Uribe AG , Jiménez-Santana L , et al . A trial contraceptive method woman systemic lupus erythematosus . N Engl J Med 2005 ; 353:2539-49 . 21 . Petri M , Kim MY , Kalunian KC , et al . Combined oral contraceptive woman systemic lupus erythematosus . N Engl J Med 2005 ; 353:2550-8 . 22 . Arden NK , Lloyd ME , Spector TD , Hughes GRV . Safety hormone replacement therapy ( HRT ) systemic lupus erythematosus ( SLE ) . Lupus 1994 ; 3:11-3 . 23 . Kreidstein S , Urowitz MB , Gladman DD , Gough J . Hormone replacement therapy systemic lupus erythematosus . J Rheumatol 1997 ; 24:2149-52 . 24 . Mok CC , Lau CS , Ho CT , Lee KW , Mok MY , Wong RW . Safety hormonal replacement therapy postmenopausal patient systemic lupus erythematosus . Scand J Rheumatol 1998 ; 27:342-6 . 25 . Buyon JP , Petri MA , Kim MY , et al . The effect combine estrogen progesterone hormone replacement therapy disease activity systemic lupus erythematosus : A randomized trial . Ann Intern Med 2005 ; 142:953-62 . 26 . - Bombardier C , Gladman DD , Urowitz MB , Caron D , Chang CH , Committee Prognosis Studies SLE . Derivation SLEDAI . Arthritis Rheum 1992 ; 35:630-40 . 27 . - Petri M , Genovese M , Engle E , Hochberg M. Definition , Incidence , Clinical Description Flare Systemic Lupus Erythematosus . Arthritis Rheum 1991 ; 34:937-44 . 28 . Gladman DD , Ibañez D , Urowitz MB . Systemic lupus erythematosus disease activity index 2000 . J Rheumatol 2002 ; 29:288-91 . 29 . Greene JG . Constructing standard climacteric scale . Maturitas 1998 ; 29:25-31 . 30 . Beck AT , Steer RA , Brown GK . Beck Depression Inventory –Second Edition Manual . San Antonio ( TX ) : The Psychological Corporation ; 2000 . 31 . - Tan EM , Cohen AS , Fries JF , Masi AT , McShane DJ , Rothfield NF , et al . The 1982 revise criterion classification Systemic Lupus Erythematosus . Arthritis Rheum 1982 ; 25:1271-7 . Supported Consejo Nacional de Ciencia Tecnología de México ( CONACYT ) ( Grant 3367P-M ) . The hormone therapy calcium provide Wyeth México Whitehall-Robbins , respectively ; neither company participate trial design , gather analysis data , write manuscript . Computer facility Department Reproductive Biology serve undertake study . Administrative clerk , health auxiliary nurse Rheumatology Reproductive Health Clinics give overall support study , without additional payment . Compensations overtime payment principal investigator research assistant available . Medical cost side effect appear within study cover Institute .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Eligible woman two follow criterion 1 . Amenorrhea 6 month . 2 . Serum folliclestimulating hormone level 30 IU/L . 3 . Menopausal symptom . 4 . Age 48 year old . 1 . Women old 65 year . 2 . Severe lupus activity baseline ( SLEDAI score , 30 ) . 3 . Use estrogens within 3 month screen visit . 4 . Serum creatinine 2.0 mg/dL . 5 . Hypertriglyceridemia 500 mg/dL . 6 . Metabolic bone disease . 7 . Liver disease . 8 . Untreated hyperthyroidism . 9 . Recent thrombosis . 10 . Malignancy . 11 . Endometrial hyperplasia . 12 . Undiagnosed uterine bleed cervical dysplasia</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>Systemic lupus erythematosus</keyword>
	<keyword>Menopause hormonal therapy</keyword>
	<keyword>Menopausal symptom</keyword>
	<keyword>Bone mineral density</keyword>
</DOC>